Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market [Seeking Alpha]
Harrow, Inc. (HROW)
Last harrow, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
HROW's recent 35% stock pullback post-Q4 2025 is attributed to conservative 2026 guidance, not deteriorating fundamentals, presenting a compelling buying opportunity. Vevye and Iheezo, HROW's flagship drugs, are set for significant revenue acceleration through expanded insurance coverage, salesforce doubling, and clinical trial catalysts. Guidance for $250M Q4 2027 revenue, robust EBITDA scaling, and a diversified drug pipeline underpin a clear path to a triple-digit share price in 2027. Looking for more investing ideas like this one? Get them exclusively at Concentrated Value with MVI. Learn More » allanswart/iStock via Getty Images Harrow, Inc. ( HROW ) is emerging as a dominant player in the US ophthalmic pharmaceuticals space. The company has grown revenue almost 30-fold since it began operations in 2015, led by its ambitious and entrepreneurial CEO, Mark Baum. In More on my IG service Thanks for reading my research. If you want to learn even more about my research
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow (HROW) had its "buy" rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.MarketBeat
- Harrow (HROW) was downgraded by Nomura to "neutral".MarketBeat
- Harrow (HROW) had its "buy" rating reaffirmed by BTIG Research. They now have a $63.00 price target on the stock.MarketBeat
- Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual MeetingGlobeNewswire
HROW
Earnings
- 3/2/26 - Miss
HROW
Sec Filings
- 3/11/26 - Form SCHEDULE
- 3/10/26 - Form 8-K
- 3/5/26 - Form 4
- HROW's page on the SEC website